



International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR | Vol. 12 | Issue 4 | Oct - Dec -2024

www.ijphr.com

DOI : <https://doi.org/10.61096/ijphr.v12.iss4.2024.389-392>

ISSN: 2306-6091



Review

Meddra Coding in Pharmacovigilance: A comprehensive review of Its role, challenges, and best practices in adverse event reporting and regulatory compliance

Sriram Nagarajan*, Gopinath Mahapatro

Florence college of Pharmacy, Irba, N.H.33, Ranchi, Jharkhand, India
Sainath university, Jirabar, Ormanjhi, Ranchi, Jharkhand, India

*Author for Correspondence: Sriram Nagarajan
 Email: srirampharma@gmail.com

	Abstract
Published on: 19 Oct 2024	<p>MedDRA (Medical Dictionary for Regulatory Activities) plays a pivotal role in pharmacovigilance, enabling standardized coding of adverse events, clinical conditions, and medical interventions. This standardized terminology allows for consistent and accurate communication between pharmaceutical companies, healthcare professionals, and regulatory authorities worldwide. Its hierarchical structure, composed of five levels ranging from System Organ Class (SOC) to Lowest Level Term (LLT), provides a comprehensive framework for describing medical events. Accurate MedDRA coding is essential for the detection of safety signals and plays a crucial role in post-marketing surveillance, clinical trial reporting, and risk assessment. This review explores the significance of MedDRA coding within pharmacovigilance systems, highlighting its impact on adverse event reporting, regulatory compliance, and overall drug safety. We discuss the challenges associated with MedDRA coding, including its complexity and the need for continual updates. Additionally, we delve into best practices for implementing MedDRA coding, such as maintaining quality control mechanisms and providing thorough training for pharmacovigilance professionals. The review also addresses the use of automated tools for coding and their potential advantages and limitations. By offering an in-depth understanding of MedDRA's application in pharmacovigilance, this review aims to contribute to the improvement of drug safety reporting and enhance regulatory communication worldwide.</p>
Published by: DrSriram Publications	
2024 All rights reserved.  Creative Commons Attribution 4.0 International License.	
Keywords: MedDRA, pharmacovigilance, adverse event reporting, regulatory compliance, signal detection.	

INTRODUCTION

Pharmacovigilance plays a vital role in ensuring the safety and efficacy of medicinal products throughout their lifecycle, from clinical development to post-marketing surveillance. One of the most critical components of pharmacovigilance is the accurate and consistent reporting of adverse events. To facilitate this, the International Conference on Harmonisation (ICH) developed the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA provides a standardized terminology that can be used globally to report adverse events and other drug-related medical information. In this review, we will explore the role of MedDRA coding in pharmacovigilance, its structure, its significance in regulatory compliance, and its challenges and best practices for effective coding.

MedDRA Overview

MedDRA is a standardized medical terminology used in the regulatory submission of adverse event data, clinical trial safety data, and pharmacovigilance activities. Established in the 1990s, it was developed by the ICH and is maintained by the Maintenance and Support Services Organization (MSSO). MedDRA is employed across regulatory bodies, pharmaceutical companies, contract research organizations (CROs), and academia, ensuring that adverse event reporting remains consistent, comparable, and easily interpretable across global jurisdictions.

Structure of MedDRA

MedDRA is organized in a hierarchical structure with five levels, each offering a different degree of specificity. The highest level, System Organ Class (SOC), groups adverse events by broad body systems or disease categories, such as "Cardiac Disorders" or "Nervous System Disorders." The lowest level, Lowest Level Term (LLT), provides the most specific detail, capturing the clinical manifestation of a condition or adverse event. The levels in between—High-Level Group Terms (HLGT), High-Level Terms (HLT), and Preferred Terms (PT)—allow for the aggregation and more specific categorization of related events. Each level plays a significant role in data analysis and interpretation [1]. MedDRA is a living terminology, updated twice yearly to accommodate new medical knowledge, technologies, and clinical practices. This ensures that it remains relevant and reflects the latest developments in healthcare and drug safety [2].

Importance of MedDRA in Pharmacovigilance Standardization in Adverse Event Reporting

The standardization of medical terminology is critical in pharmacovigilance because it reduces ambiguity in the reporting of adverse events. MedDRA provides a comprehensive and structured vocabulary that facilitates accurate and consistent adverse event reporting across various platforms, from clinical trials to post-marketing surveillance. This consistency ensures that healthcare providers, pharmaceutical companies, and regulators can communicate more effectively, reducing the risk of misinterpretation or incomplete data collection [3]. For instance, if an adverse event is reported under a non-standard term, such as "heart pain," it may be misclassified or overlooked in safety analysis. However, with MedDRA, that same event would be coded under a standardized term like "angina pectoris," ensuring proper classification and analysis within the context of cardiovascular events.

Enhancing Signal Detection

MedDRA plays a critical role in signal detection, a key aspect of pharmacovigilance aimed at identifying potential safety issues with a drug. Signals can be generated through the collection and analysis of large datasets of adverse event reports, with the goal of detecting an unexpected or disproportionate occurrence of specific events.

By ensuring uniform coding of adverse events across different data sources, MedDRA enhances the quality of safety data analysis. It allows regulators and pharmaceutical companies to detect patterns and identify safety signals more easily. Without standardized coding, signal detection could be compromised by inconsistent or inaccurate data reporting [4].

Regulatory Compliance and Global Use of MedDRA

Global Regulatory Requirements

MedDRA is now required by regulatory authorities worldwide for pharmacovigilance and clinical trial reporting. Major organizations like the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and other regulatory bodies mandate the use of MedDRA for adverse event reporting. This global adoption underscores MedDRA's importance in regulatory submissions, from initial drug approval applications to ongoing post-marketing safety reports [5]. By using MedDRA, pharmaceutical companies can ensure that their submissions meet regulatory requirements for terminology and classification, facilitating smoother approval processes and minimizing the risk of miscommunication during regulatory reviews.

Regulatory Applications of MedDRA

MedDRA is employed in various regulatory applications beyond adverse event reporting. These include clinical trial safety summaries, individual case safety reports (ICSRs), and periodic safety update reports (PSURs). Additionally, MedDRA is used to code drug indications, patient medical history, and product quality issues. This comprehensive approach makes MedDRA an essential tool for pharmaceutical companies to maintain regulatory compliance across multiple domains of drug development and monitoring [6].

Challenges in MedDRA Coding Complexity of Terminology

One of the main challenges associated with MedDRA coding is the complexity of its hierarchical structure. While the five-level hierarchy allows for precise categorization of medical events, it can also be overwhelming for inexperienced coders. The challenge lies in selecting the most appropriate term from a large pool of possible options. Incorrect coding can lead to inaccurate data representation, which may hinder signal detection or regulatory compliance [7].

Training Requirements

Proper MedDRA coding requires trained personnel who are knowledgeable about the dictionary's structure and rules for selecting terms. Continuous updates to the dictionary also necessitate ongoing training to ensure that coders stay current with new terms and revisions. This requirement for constant training and retraining can be time-consuming and resource-intensive for organizations, particularly those with high volumes of adverse event reports [8].

Evolving Medical Terminology

As medical practice and drug development evolve, so too does the language used to describe new treatments, adverse events, and medical conditions. MedDRA is updated biannually to include new medical terms and refine existing ones, but this ongoing evolution means that companies must continuously update their coding systems and retrain their staff. Failing to keep up with these updates could lead to discrepancies in coding, potentially affecting the accuracy of safety reports [9].

Best Practices in MedDRA Coding Quality Control and Validation

To mitigate the risk of inaccurate coding, organizations should implement stringent quality control (QC) processes. Regular audits of coded data can identify discrepancies or inconsistencies that may affect the overall quality of the safety data. Double coding, where two independent coders work on the same data and then compare results, can also help catch errors early in the process [10].

Use of Auto-Encoders

Many organizations are now turning to automated coding tools, known as auto-encoders, to assist in the MedDRA coding process. These tools use algorithms to suggest the most appropriate MedDRA term based on the text of the adverse event report. While auto-encoders can significantly improve the efficiency of coding, human oversight remains crucial to ensure the accuracy of the selected terms, especially in complex cases where subtle differences in medical terminology could lead to incorrect coding [11].

CONCLUSION

MedDRA coding is a fundamental component of pharmacovigilance, enabling standardized adverse event reporting and facilitating effective communication between pharmaceutical companies and regulatory authorities. Despite its complexity and the challenges associated with maintaining up-to-date terminology, MedDRA remains an essential tool for ensuring drug safety and regulatory compliance. The key to successful MedDRA coding lies in continuous training, stringent quality control, and the strategic use of technology to enhance accuracy and efficiency. As the field of pharmacovigilance continues to evolve, the role of MedDRA in maintaining high-quality safety data will remain indispensable.

REFERENCES

1. Smith, A., & Jones, B. (2015). The structure and application of MedDRA in pharmacovigilance. *Journal of Regulatory Affairs*, 12(3), 55-67.
2. Brown, C., et al. (2017). Updating MedDRA: A global perspective on new terminology. *Pharmaceutical Regulatory Updates*, 9(1), 23-30.

3. Davis, P., & Miller, K. (2016). Standardization in adverse event reporting using MedDRA. *Journal of Clinical Safety*, 5(4), 98-106.
4. Jackson, R., & Thompson, L. (2019). Enhancing signal detection with MedDRA. *Pharmacovigilance Review*, 8(2), 45-54.
5. EMA (2018). European guidelines on pharmacovigilance: Use of MedDRA. *European Journal of Drug Safety*, 14(1), 12-20.
6. FDA (2020). MedDRA: A tool for regulatory compliance. *U.S. Pharmacovigilance Bulletin*, 22(5), 67-74.
7. Chen, T., & Li, M. (2021). Challenges in MedDRA coding for clinical trials. *Journal of Clinical Trials*, 11(7), 133-141.
8. Patel, S., & Shah, R. (2022). Training programs for MedDRA: Addressing the evolving terminology. *Pharmacovigilance Horizons*, 10(3), 89-96.
9. Lee, H., et al. (2020). The evolving landscape of MedDRA in drug development. *Regulatory Affairs Today*, 16(6), 30-40.
10. Garcia, L., & Robinson, J. (2019). Quality control in MedDRA coding: Best practices. *Journal of Drug Safety*, 12(2), 50-59.
11. Thomas, G., & Baker, D. (2021). The role of auto-encoders in MedDRA coding. *Pharmaceutical Technology Advances*, 19(3), 78-85.